Lexicon Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1995-01-01

Employees: 285

Market Cap: $621.7M

Website: http://www.lexpharma.com

Introduction: Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Clinical Trials

Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]-LX4211

First Posted Date: 2013-03-26

Last Posted Date: 2013-06-18

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT01818232

Locations: 🇺🇸
Lexicon Investigational Site, Madison, Wisconsin, United States

Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Sotagliflozin
Drug: Placebo

First Posted Date: 2012-12-05

Last Posted Date: 2020-02-12

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT01742208

Locations: 🇺🇸
Lexicon Investigational Site, Dallas, Texas, United States

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

Phase 3

Completed

Conditions: Carcinoid Syndrome

Interventions: Drug: Telotristat etiprate
Drug: Placebo-matching telotristat etiprate

First Posted Date: 2012-09-03

Last Posted Date: 2018-02-27

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 135

Registration Number: NCT01677910

Locations: 🇮🇱
Lexicon Invetigational Site, Jerusalem, Israel
🇬🇧
Lexicon Investigational Site, Newcastle upon Tyne, United Kingdom

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus
Renal Impairment

Interventions: Drug: LX4211
Drug: LX4211 Placebo

First Posted Date: 2012-03-15

Last Posted Date: 2013-09-09

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT01555008

Locations: 🇺🇸
Lexicon Investigational Site, Renton, Washington, United States

Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Phase 1

Completed

Conditions: Primary Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: LX7101 Vehicle
Drug: LX7101 (0.125%)
Drug: LX7101 (0.25%)

First Posted Date: 2012-02-07

Last Posted Date: 2015-09-14

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 63

Registration Number: NCT01528111

Locations: 🇺🇸
Lexicon Investigational Site, San Antonio, Texas, United States

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Phase 2

Completed

Conditions: Irritable Bowel Syndrome

Interventions: Drug: 250 mg LX1033 tablets
Drug: Placebo tablet

First Posted Date: 2011-12-16

Last Posted Date: 2015-03-23

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 373

Registration Number: NCT01494233

Locations: 🇺🇸
Lexicon Investigational Site, Virginia Beach, Virginia, United States

A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Telotristat Etiprate
Drug: Placebo

First Posted Date: 2011-10-20

Last Posted Date: 2019-05-23

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 59

Registration Number: NCT01456052

Locations: 🇸🇰
Lexicon Investigational Site, Nove Mesto nad Vahom, Slovakia

A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: LX4211
Drug: Januvia®

First Posted Date: 2011-09-27

Last Posted Date: 2012-01-31

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT01441232

Locations: 🇺🇸
Lexicon Investigational Site, San Antonio, Texas, United States

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: 50 mg LX3305 QD
Drug: 100 mg LX3305 QD
Drug: 150 mg LX3305 QD
Drug: 200 mg LX3305 QD
Drug: 250 mg LX3305 QD
Drug: 300 mg LX3305 QD
Drug: 400 mg LX3305 QD
Drug: 250 mg LX3305 BID
Drug: 500 mg LX3305 QD
Drug: Placebo